10.1161/01.ATV.0000067426.96344.32 24 BrouiletteS
Acknowledgements This work was supported by grants from the National Institutes of Health (R01HL160767 and R01HL155035), American Heart Association (19TPA34850148), and the University of Washington Royalty Research Fund
By putting everything into context by describing the BBB structure, emphasizing how the barrier alters in age and disease, and the current drugs explored to slow the negative outcomes of age and disease through acting directly on the BBB, the goal is to exploit the easily accessible and manipulable microbiota as a potential target to modulate the BBB
Yet robust clinical trials supporting specific glutathione outcomes remain sparse
Very expensive ($500-$2,000+ per treatment course)
Anti-Inflammatory and Antioxidant Potential Chronic low-grade inflammation is now considered one of the biggest drivers of aging and degenerative disease